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Abstract
Introduction and hypothesis The aim of the Incontinence
Outcome Questionnaire (IOQ) is to assess quality of life
and patient-reported outcome after midurethral slings.
Methods In this retrospective study, 626 patients with a
minimum follow-up period of 1 year were sent the IOQ.
Four hundred twenty-two of 626 (67.4%) patient responses
were evaluated.
Results The mean IOQ QoL extended score was 33.7±17.5
and comparable for tension-free vaginal tape (TVT), outside-in
transobturator tape (TOT), and inside-out transobturator
vaginal tape (TVT-O). Evaluation of IOQ question about
readmission revealed a total of 32 patients (18 TVT, 12 TOT,
and 2 TVT-O) who underwent a subsequent operation due to
sling-related complications. Freedom from reoperation for
recurrent SUI at 1, 2, and 5 years was 100%, 99.7±0.3%, and
99.7±0.3% for TVT, 100% for TVT-O, and 94.2±2.5%,
91.9±2.9%, and 89.9±3.5% for TOT, respectively (p<0.001).
Conclusions Patient satisfaction, assessed using the IOQ, is
high after retropubic and transobturator slings. In our
collective, relapse incontinence is higher after TOT.
Keywords Incontinence Outcome Questionnaire (IOQ) .
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Introduction
Urinary incontinence defined as any involuntary loss of
urine has a negative impact on the social, physical, and
psychological life of women affected [1, 2]. The current
evidence base for the surgical treatment of stress urinary
incontinence (SUI) suggests that the insertion of a
midurethral tape will become the treatment of choice [3].
For the retropubic route—first introduced as tension-free
vaginal tape (TVT) by Ulmsten and Petros in 1995—long-
term results of up to 11 years are well documented and
continence rates of 90 % are reported [4, 5]. In 2001,
Delorme introduced an outside-in transobturator tape
(TOT) [6] and in 2003, de Leval introduced the inside-
out transobturator vaginal tape (TVT-O) [7]. Subsequent
publications for transobturator slings cover only short- to
mid-term follow-up of a maximum of 3 years [8]. Overall,
all tapes establish continence effectively and can be
considered as safe and durable surgical procedures for
SUI [5, 9].
Operations for urinary incontinence seldom lead to
severe morbidity and the primary impact is on improved
quality of life (QoL) and patient satisfaction. The ICS
standardization committee emphasizes the importance of
postoperative survey on subjective outcome, patient
satisfaction, and health-related quality of life parameters
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measured by specific questionnaires [8]. In the fourth
edition of the International Consultation on Incontinence,
self-completed patient questionnaires are considered to
represent the best clinical review of symptom impact and
treatment benefit. QoL after sling procedures was the
objective of several trials using different incontinence-
specific questionnaires like the Urogenital Distress Inven-
tory (UDI-6) [10], Incontinence Impact Questionnaire
(IIQ-7) [5, 11, 12], Incontinence Severity Index (ISI),
Pelvic Floor Distress Inventory, Short Form-20 (PFI-20),
Pelvic Floor Impact Questionnaire-Short Form-7 (PFIQ-7),
and the Pelvic Organ Prolapse/Urinary Incontinence Sexual
Questionnaire-Short Form (PISQ-12) [13]. Significant
improvements of QoL after sling procedures have been
shown for retropubic and transobturator slings and are
persistent for up to 11 years. In order to evaluate QoL and
postoperative patient satisfaction without preoperative base-
line data, a specific one-point measurement instrument is
needed. Therefore, a detailed 27-item Incontinence Outcome
Questionnaire (IOQ), validated for the German language,
was constructed to assess patient-reported outcome and QoL
after insertion of a midurethral tape [14]. The IOQ is
considered as a valid and reliable instrument when baseline
or preoperative data is unavailable because of the partial
correlation with objective clinical parameters such as
continence. Our study was designed to answer the following
primary question: How is the patient satisfaction 1 year or
more after midurethral sling procedure using the IOQ?
Secondary questions were the applicability of the IOQ 1 year
and more after operation and differences in outcome
parameters among different sling types.
Material and methods
Patient and preoperative evaluation
In this retrospective study, 626 women who underwent
midurethral sling surgery at two medical centers (one
university hospital and one district hospital) between
January 1999 and December 2007 were identified as
follows using a computerized medical record system:
452 (72.2 %) TVT, 119 (19.0 %) TOT (Monarc), 36
(5.8%) TVT-O, 9 (1.4 %) intravaginal sling (IVS), and
10 (1.6 %) readjustable sling system (Remeex). The
minimal follow-up after operation was determined as
1 year. All patients were evaluated preoperatively by
means of a patient history, gynecological examination
with a positive cough test, and urine control (dipstick) to
exclude a urinary tract infection. All subjects had a
clinical SUI. The inserted TVT and TVT-O were
manufactured by Ethicon, Neuchâtel, Switzerland and
distributed by Gynecare Switzerland; the TOT Monarc®
was manufactured by American Medical Systems,
Minnetonka, USA and distributed by Promedics, Switzerland.
Ten surgeons, trained in urogynecological surgery, performed
the operations according to the original methods. Every
surgeon was carrying out all three sling procedures. The
anesthesia was usually local anesthesia or dependent on
concomitant surgery.
Ethical approval was obtained from the ethics commit-
tees of Zurich University Hospital and Altdorf District
Hospital, Canton Uri. This clinical trial has been registered
at http://www.clinicaltrials.gov, and the identification num-
ber is NCT01042275.
Outcome measures
The IOQ consisting of 27 questions were sent by mail to all
patients identified. Patients who did not respond to the first
mailing received a second mail. The IOQ consists of 27
questions comprised as follows: four related to symptoms
[pain, postoperative symptoms, preoperative overactive
bladder (OAB), and change in OAB symptoms pre or
postoperatively], four about complications (urinary or other
infection, hospital readmission, and residual urine), seven
about QoL (felt tired/drained/lacking energy, felt irritable/
snappy, felt depressed/tearful, general evaluation of health,
limitations in daily activities, change in sexual activity, and
change in body perception), five about satisfaction (changes
of symptoms pre and postoperatively, time of recovery,
satisfaction with information, improvement in well-being,
and recommending the operation), one about problems with
urinary incontinence before surgery, and six address
demographic and treatment-related information (age, occu-
pation, living arrangements, reason for operation, hormone
replacement therapy, and time interval to operation). Each
item is rated onto a 0–100 scale (0=minimum, 100=
maximum impairment), from which two scores are calcu-
lated: one for the seven QoL and the five satisfaction
questions, and an extended score which includes additional
questions about postoperative symptoms, post-void residual
urine volume, and change in OAB symptoms as well. A
visual analogue scale was added (VAS, where 0 means no
urinary problems and 10 means unbearable urinary prob-
lems) to assess the subjective grade of discomfort for urine
loss pre and postoperatively. Further analysis of the answers
related to readmission (IOQ4) was carried out by cross-
checking patient answers and remarks with our clinical
information system.
Statistics
All patients who completed the questionnaire following
TVT, TOT Monarc, or TVT-O procedure were included
for statistical analysis. Statistic evaluation was carried
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out with the Kruskal–Wallis, chi-square, or Fisher’s exact
test as appropriate, using Intercooled Stata 10.0. Contin-
uous data are presented as mean±standard deviation.
Two-sided p values≤0.05 are considered statistically
significant. Readmission and reoperation due to relapse
incontinence was examined with the Kaplan–Meier anal-
ysis and log-rank test. The time analysis was measured in
years, expressing the time period between the sling
insertion and readmission, respectively, the second sling
operation. No power analysis was performed due to the
retrospective design.
Results
Five hundred twenty (83%) of the 626 questionnaires sent
were returned, of which 434/626 (69.1%) were completed
IOQ questionnaires, 55 (8.8%) were returned by the post
office (address not known in the electronic telephone directory
and no addendum in the internal address system), 21 (3.4%)
women had died, 6 (1%) patients returned a blank IOQ, 4
questionnaires (0.6%) could not be properly evaluated
because of serious cognitive disorders, and 108 (17.3%) were
not returned by the patients. IVS and Reemex interventions
were excluded from further evaluation because of the small
number of patients (<2% of all operations) and the different
material of the sling. The following analysis included the 422
patients who had TVT, TOT, or TVT-O. Among this group,
patient compliance was good with a maximum of 2.7% (1.3–
5.7%) of missing data per item.
The distribution of the slings during the observation
period is shown in Fig. 1. Two hundred seventy-eight of
the 422 eligible patients had a preoperative urodynamic
evaluation (65.9%). Table 1 shows the basic character-
istics. With the exception of the lower age of the TVT
group and the higher age in the TOT group, the three
groups TVT, TOT, or TVT-O did not differ significantly in
relation to preoperative basic characteristics such as body
mass index, parity, history of smoking, hormone replace-
ment therapy, and urodynamic parameters such as maxi-
mum urethral closure pressure, volume at first desire to
void, and bladder capacity, where these data was available.
Twenty-five patients had previous incontinence surgery,
showing no statistically significant difference among the
three groups (p=0.19, Fisher’s exact test). Concomitant
prolapse surgery was performed in a total of 63 patients
with clinical SUI (p=0.11, Fisher’s exact test).
At the time of completion of the IOQ, the overall mean
follow-up was 4.9±2.3 years. The mean follow-up of the
TVT group (5.5±2.4 years) was significantly longer than of
the TOT (3.6±1.1 years) or TVT-O (2.9±1.0 years) group
(p<0.001), due to the gradual introduction of these different
sling techniques.
The total impact of postoperative incontinence on QoL,
as measured by means of VAS and IOQ scores, did not
differ for the sling types, as shown in Table 2. With the
exception of the IOQ5 score (feeling tired/drained/lacking
energy), the subjective outcomes were comparable between
the groups. The postoperative change in the sex life of the
respondents shows a tendency in favor of the TVT and
TVT-O sling, but is not statistically significant (p=0.056).
The evaluation of question IOQ4 about readmission
revealed a total of 32 patients who underwent a second
sling-related operation [18 TVT (5.9%), 12 TOT
(13.6%), 2 TVT-O (7.1%)]. The percentage of patients
without a second intervention after 1, 2, and 5 years is
described as freedom from reoperation. Freedom from
reoperation at 1, 2, and 5 years was 95.8±1.1%, 95.4±
1.2% and 93.9±1.5% for TVT, 92.9±4.9% for TVT-O,
and 93.1±2.7%, 88.3±3.5%, and 86.1±4.0% for TOT,
respectively (p=0.029, log-rank test) (Fig. 2). Partial tape
excision or resuturing of the vaginal wall due to tape
erosion was performed in ten patients (seven TVT (2.3%),
three TOT (3.4%), and zero TVT-O). Complete tape
incision was performed on 12 patients due to bladder
outlet obstruction, recurrent urinary tract infections, or de
novo urge [ten TVT (3.3%), one TOT (1.1%), and one
TVT-O (3.6%)]. Owing to relapse of stress urinary
incontinence, ten patients (one TVT (0.3%), eight TOT
(9.0%), and one TVT-O (3.6%)) received a second tape
(nine TVT, one Remeex). One patient underwent an
intravesical injection of botulinum toxin due to urge
incontinence 15 months after insertion of a TOT and an
antecedent tape incision. None of the patients with a
repeat incontinence procedure had a prior incontinence
surgery. Freedom from reoperation for recurrent SUI at 1,
2, and 5 years was 100%, 99.7±0.3% and 99.7±0.3% for
TVT, 100% for TVT-O, and 94.3±2.5%, 91.8±3.0%, and
89.9±3.7% for TOT, respectively (p<0.001) (Fig. 3).
Fig. 1 Distribution of the sling types inserted during observation
period 1999–2007 in the 422 eligible patients
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Discussion
In order to determine the efficacy of any treatment
modality, the impact of the procedure on patient’s quality
of life and long-term satisfaction must be evaluated and
reported. This information needs to be provided in order for
patients to make an accurately informed decision regarding
their therapy. To the best of our knowledge, this is the first
clinical application of the IOQ for assessing patient
satisfaction in a clinical trial. An advantage of the IOQ is
that it is applicable for posttreatment assessment of QOL
following surgery for incontinence within the scope of
clinical studies or as a quality control tool when preoper-
ative questionnaires are not collected.
The IOQ provides information on QoL, patient satisfac-
tion, and complication rate in an accurate and comprehen-
sive way after more than 1 year after operation. Up to now,
no long-term data for acceptability, reliability, and validity
of the IOQ were available [15].
Patient compliance was excellent as in the original
publication, with less than 4% missing data [15]. This
was achieved in a collective study where 26.1% of patients
were older than 70 years.
Mean follow-up for TVT (5.4 years) was obviously
longer than for TOT (3.5 years) and TVT-O (2.9 years), as
these were introduced subsequently in our clinic.
Outcome parameters for QoL and subjective conti-
nence are similar for all three sling types, showing no
time-related decrease. This finding is corresponding with
other studies providing subjective outcomes using vali-
dated questionnaires like the UDI-6 and IIQ-7, where the
scores for retropubic and transobutrator slings were
similar. Notably, retropubic slings were followed by
significantly higher objective continence rates [15]. As
Table 1 Basic characteristics including preoperative urodynamic data of the 422 eligible patients. Data is expressed as mean±standard deviation
(eligible patients in parenthesis) or number of patients (percentage)
N TVT (pts.) TOT Monarc (pts.) TVT-O (pts.) p Value
306 (72.5%) 88 (20.9%) 28 (6.6%) –
Age at operation (years) 59.7±12.2 65.0±12.9 62.2±13.8 0.003a
Body mass index (kg/m2) 26.8±4.9 26.2±4.4 27.7±4.6 0.32a
(286) (78) (28)
Parity 2.5±1.1 2.6±1.3 2.5±1.0 0.85a
(277) (76) (22)
History of smoking 103/300 27/86 5/27 0.24a
(34.2%) (31.4%) (18.5%)
Hormone replacement therapy 71/300 (23.7%) 17/85 (20.0%) 7/28 (25.0%) 0.60a
Urodynamic data
Maximum urethral closure pressure (cmH2O) 43.3±23.3 (203) 38.6±19.1 (45) 51.7±26.9 (19) 0.18
a
Volume at first desire to void (ml) 244.9±108.0 (208) 234.3±120.3 (46) 264.0±104.5 (19) 0.41a
Maximum bladder capacity (ml) 452.9±104.8 (208) 424.4±128.4 (48) 479.1±108.7 (20) 0.21a
Preoperative post-void residual urine volume (ml) 19.6±41.3 (180) 28.1±64.8 (37) 28.2±30.3 (19) 0.13a
Short-pad test (g) 67.8±68.2 (207) 60.4±66.0 (44) 107.5±137.2 (18) 0.25a
Previous incontinence surgery 0.19b
Abdominal colposuspension 11 0 3
Vaginal colposuspension 5 0 3
Sling insertion 0 1 0
Botulinum toxin intravesical 1 0 0
Sling and botulinum toxin 0 0 1
Concomitant prolapse surgery 39 19 5 0.11a
Hysterectomy 19 9 2 0.42b
Colporrhaphia anterior 28 10 4 0.47b
Colporrhaphia posterior 23 11 2 0.36b
Sacrospinous ligament fixation 4 6 0 0.02b
Botulinum toxin intravesical 1 3 1 0.02b
TVT tension-free vaginal tape, TOT outside-in transobturator tape, TVT-O inside-out transvaginal tape, Pts number of eligible patients
a Kruskal–Wallis
b Fisher’s exact test
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short-term results of the TVT procedure are encouraging
[16] and were supported by several authors [17, 18], long-
term results after sling insertion have been published in
the last few years [5, 12–14, 19]. Like the Burch
colposuspension, there seems to be a surgical success
decline with TVT procedure after 5- and 7-year follow-up
[20].
Objectively, we found an increased recurrence rate of
incontinence in the TOT group leading to a significantly
smaller freedom from reoperation. This might be a reason
why women with a TOT were the less satisfied with the
preoperative information (IOQ16). The informed consent
forms for all sling operations were the same and can be
downloaded from the homepage of the Swiss Society of
Obstetrics and Gynecology.
Repeated procedures for incontinence are known to
increase the risk of surgical failure after incontinence
surgery [21, 22]. Although it might be expected that
recurrent incontinence could result from previous inconti-
nence surgery, none of our patients with a recurrence of
SUI after sling procedure had had any prior incontinence
surgery, and the preoperative MUCP did not differ among
the groups [23]. There is a lack of data and guidelines for
treatment of recurrent SUI and there is no clear guidance
regarding the approach for secondary surgery which would
offer the best result [24]. In our observational study, all
Table 2 Postoperative subjective long-term results. Data are expressed as mean±standard deviation (range)
TVT (306) TOT Monarc (88) TVT-O (28) p Value
Follow-up (time interval between operation and completion of IOQ, in years) 5.5±2.3 3.6±1.1 2.9±1.0 <0.001a
(1.2–10.0) (1.7–6.2) (1.7–4.9)
VAS preoperative (0–10) 7.9±1.8 7.9±1.8 7.7±2.3 0.97a
VAS postoperative (0–10) 2.4±2.6 2.1±2.9 2.3±2.9 0.21a
Symptoms
Pain (IOQ1) 9.9±21.9 7.5±15.3 8.9±16.0 0.97a
Symptoms preoperative (IOQ8) 76.7±23.4 75.0±24.0 71.4±28.6 0.65a
Symptoms postoperative (IOQ9) 18.1±26.7 22.1±30.4 15.2±25.8 0.51a
OAB preoperative (IOQ20) 74.4±43.7 80.0±40.2 85.2±36.2 0.30a
Change in OAB symptoms pre or postoperative (IOQ21) 30.1±27.5 27.8±29.3 22.3±22.1 0.33a
Complications
Urinary infection (IOQ2) 37.4±48.5 29.9±46.0 33.3±48.0 0.42a
Other infection (IOQ3) 19.1±39.4 12.9±33.8 21.4±41.8 0.38a
Hospital readmission (IOQ4) 7.1±25.7 14.8±35.7 7.1±26.2 0.08a
Residual urine (IOQ19) 28.7±25.3 31.2±28.8 26.8±26.3 0.81a
Quality of life
Felt tired/drained/lacking (IOQ5) 42.2±28.3 41.2±28.0 23.2±25.4 0.003a
Felt irritable/snappy (IOQ6) 38.1±28.0 34.1±24.7 28.6±31.7 0.13a
Felt depressed/tearful (IOQ7) 38.1±29.9 36.6±27.0 35.7±35.6 0.83a
Global evaluation of health (IOQ10) 43.8±21.5 44.2±22.6 46.4±26.1 0.64a
Limitations in daily activities (IOQ12) 30.9±30.2 31.2±32.7 28.6±28.6 0.95a
Change in sex life (IOQ13) 52.6±35.7 63.2±35.8 55.1±37.6 0.06a
Change in feeling about body (IOQ14) 25.3±30.2 27.9±33.1 23.2±28.8 0.82a
Satisfaction
Symptoms changes pre and postoperative (IOQ11) 14.1±25.5 17.7±30.2 17.9±30.3 0.73a
Time of recovery (IOQ15) 33.7±30.6 38.8±37.2 32.1±33.9 0.67a
Satisfaction with information (IOQ16) 50.0±15.3 54.9±18.6 46.4±18.9 0.02a
Improvement in well-being (IOQ17) 19.9±27.9 21.6±29.6 15.2±25.8 0.57a
Recommending operation (IOQ18) 15.2±29.6 19.4±32.1 14.3±30.7 0.35a
IOQ QoL Score (0-100) 33.6±17.2 35.3±18.6 30.8±18.1 0.57a
IOQ QoL extended score (0–100) 31.9±16.9 33.7±18.9 27.9±17.9 0.35a
TVT tension-free vaginal tape, TOT outside-in transobturator tape, TVT-O inside-out transvaginal tape, IOQ Incontinence Outcome Questionnaire,
VAS visual analogue scale, OAB overactive bladder, QoL quality of life
a Kruskal–Wallis test
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secondary inserted slings were inserted by the retropubic
route (11 TVT, 1 Remeex). Recently, lower failure rates
following retropubic slings have been published and there
is some evidence to consider the insertion of a retropubic
sling in the case of primary failure [25, 26].
There was no difference in the reporting of voiding
difficulties (IOQ19) in our midterm follow-up, in contrast
to a recent meta-analysis, where TOT and TVT-O caused
less voiding difficulties [27]. However, the readmission rate
for sling release because of voiding difficulties (1 day–
45 months after operation) as controlled by the clinical
information system, was higher in the TVT group but not
yet statistically significant.
Weaknesses of the study are the not uniform sample size
with a majority of TVT, the varying length of follow-up,
the differences in age, and the inhomogeneous distribution
of concomitant procedures due to the retrospective design
of this study. Another flaw is the possible incorrect
completion of questions like IOQ4 about readmission
(yes/no and the cause of the readmission). To avoid
misinterpretation, patient remarks about the reason for
readmission must be checked against a clinical information
system. After cross-checking, the patients answer with the
clinical information system, we state that most patients
reported the diagnosis of relapse incontinence correctly,
whereas voiding difficulties resulting as a consequence of
too tense slings or tape erosions were reported by related
symptoms such as urinary tract infection or incomplete
bladder emptying. As the IOQ was designed for application
3 months after operation, some questions like IOQ5 (felt
tired/drained/lacking) and IOQ6 (felt irritable/snappy) are
not appropriate questions in a follow-up longer than
3 months. The symptoms of fatigue and irritability are
mostly dependent on a short date back operation or
anesthesia.
The slightly lower age in the TVT group is explained
by a possible selection bias. In the early stage, we
preferred the transobturator route for older patients based
on the rationale that this technique is less obstructive,
while later the established retropubic route was preferred
for younger and sexually active patients in order to avoid
pain-related sexual dysfunction caused by the TO
passage [28, 29].
Most of the recurrent cases were in the TOT group.
Except the older age of these patients, we do not have an
explanation for this observation and cannot exclude bias.
The retrospective design of this study is a further
weakness due to missing preoperative data such as the
VAS for incontinence distress symptoms. The VAS for
preoperative incontinence distress symptoms was col-
lected by the IOQ at time the questionnaire was
completed, and this might be a recall bias and not
represent the real discomfort the incontinence caused to
the patient preoperatively. Nevertheless, the VAS has
been proven to be a reliable and reproducible method
for the assessment of quality of life in urogynecological
research [30].
The IOQ is categorized as a level C grade of recom-
mendation by the fourth edition of the International
Consultation on Incontinence, which implies that a ques-
tionnaire is in the early development stage and has future
potential but that further work is required and encouraged
[10]. In our analysis, the IOQ proved to be a valuable and
proper instrument to assess the subjective patient mid- to
long-term outcome on various emotional, physical, and
social states, as well as on symptom distress data and
readmission rate following sling surgery. Further studies are
required to affirm our results.
Fig. 3 Kaplan–Meier curve for second sling insertion due to relapse
incontinence depending on sling type. Log rank test (Mantel–Cox) for
equality of relapse incontinence functions p=<0.001
Fig. 2 Kaplan–Meier curve for reoperation depending on sling type. Log
rank (Mantel–Cox) test for equality of readmission functions p=0.029
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Conclusion
Patient assessment using the IOQ showed that all sling
procedures restore continence effectively with compara-
ble mid-term outcome in relation to quality of life in
women with stress urinary incontinence. In our survey,
a higher postoperative incontinence rate was shown with
TOT slings compared to TVT, and this occurred within
a shorter observational interval. This raises the question
whether TOT will maintain comparable long-term
efficacy as TVT.
Conflicts of interest None.
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